Tracking Chlamydia - Host interactions and antichlamydial activity in Caenorhabditis elegans

Biomed Pharmacother. 2024 Aug:177:116956. doi: 10.1016/j.biopha.2024.116956. Epub 2024 Jun 19.

Abstract

The fading efficacy of antibiotics is a growing global health concern due to its life-threatening consequences and increased healthcare costs. Non-genetic mechanisms of antimicrobial resistance, such as those employed by Chlamydia pneumoniae and Chlamydia trachomatis, complicate treatment as these bacteria can enter a non-replicative, persistent state under stress, evading antibiotics and linking to inflammatory conditions. Understanding chlamydial persistence at the molecular level is challenging, and new models for studying Chlamydia-host interactions in vivo are urgently needed. Caenorhabditis elegans offers an alternative given its immune system and numerous orthologues of human genes. This study established C. elegans as an in vivo model for chlamydial infection. Both Chlamydia species reduced the worm's lifespan, their DNA being detectable at three- and six-days post-infection. Azithromycin at its MIC (25 nM) failed to prevent the infection-induced lifespan reduction, indicating a persister phenotype. In contrast, the methanolic extract of Schisandra chinensis berries showed anti-chlamydial activity both in vitro (in THP-1 macrophages) and in vivo, significantly extending the lifespan of infected C. elegans and reducing the bacterial load. Moreover, S. chinensis increased the transcriptional activity of SKN-1 in the worms, but was unable to impact the bacterial load or lifespan in a sek-1 defective C. elegans strain. In summary, this study validated C. elegans as a chlamydial infection model and showcased S. chinensis berries' in vivo anti-chlamydial potential, possibly through SEK/SKN-1 signaling modulation.

Keywords: Bacterial persistence; Dibenzocyclooctadiene lignan; Non-genetic antimicrobial resistance; Pathogen-host interaction; Phytomedicine; Schisandra chinensis.

MeSH terms

  • Animals
  • Anti-Bacterial Agents* / pharmacology
  • Azithromycin / pharmacology
  • Caenorhabditis elegans Proteins* / genetics
  • Caenorhabditis elegans Proteins* / metabolism
  • Caenorhabditis elegans* / drug effects
  • Caenorhabditis elegans* / microbiology
  • Chlamydia Infections* / drug therapy
  • Chlamydia Infections* / microbiology
  • Chlamydia trachomatis / drug effects
  • Chlamydophila pneumoniae / drug effects
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / metabolism
  • Host-Pathogen Interactions
  • Humans
  • Longevity / drug effects
  • Plant Extracts / pharmacology
  • THP-1 Cells
  • Transcription Factors / genetics
  • Transcription Factors / metabolism

Substances

  • Caenorhabditis elegans Proteins
  • Anti-Bacterial Agents
  • Plant Extracts
  • DNA-Binding Proteins
  • skn-1 protein, C elegans
  • Transcription Factors
  • Azithromycin